7:30 am Coffee & Registration

8:30 am Chair’s Welcoming Remarks

Assessing The Strategic Value Of 3D Models

8:40 am Beyond 3D-Models – Building Confidence in Microphysiological Models at Novartis


  • Divulging Novartis’ approach to 3D microphysiological systems
  • Exploring common drug development issues to frame specific questions and highlighting how 3D tumour models can address these
  • Illustrating case studies of how Novartis are using microphysiological systems in current projects and future plans

9:10 am Utilizing Multicellular 3D Models for Preclinical Drug Discovery

  • Anita Seshire Head of Laboratory Cellular Pharmacology & Translational Innovation Platform Oncology , EMD Serono


  • Developing primary 3D cell cultures from patient material
  • Addition of monocytes or fibroblasts to identify a potential trophic role
  • Transplantation of multicellular spheres to create tumours with microenvironments and enable the exploration of the influence of the TME on stemness

9:40 am Speed Networking & Morning Refreshments

10:40 am KEYNOTE: Transforming Translational Research: CANscript™ – A Better Predictive Model for Oncology

  • Mark Paris Director, Translational Applications, Mitra Biotech


  • Mitra Biotech has developed and clinically validated our fully human ex vivo platform technology (CANscript™)
  • CANscript ™ uses fresh patient material (tumor, autologous ligands and PBMCs) to explore the mechanism of action by employing customizable endpoint assays
  • This talk will focus on how we use CANscript to explore the effect of checkpoint inhibitors alone and in combination with SOC as well as oncolytic virus to answer development-critical questions

11:10 am Panel Discussion: How, When, Where?! Selecting and Choosing the Right 3D System

  • Szczepan Baran Head of Emerging Technologies , Novartis
  • Mark Paris Director, Translational Applications, Mitra Biotech


  • Where should 3D models be qualified and successfully integrated into the R&D paradigm?
  • What are the remaining challenges that are yet to be addressed for integration of these models?
  • Where have 3D Models failed to exact their promise?
  • What are the pitfalls of classical animal models that 3D models are fulfilling?

Strategies For Understanding & Targeting The Microenviroment

11:40 am A Microfluidic Platform for Rapid and Predictive Assessment of Immune Checkpoint Inhibitor Efficacy in Mouse and Human Tumors


  • Technologies for increasing the throughput and accuracy of immune checkpoint inhibitor efficacy against human cancers are badly needed
  • Existing models typically utilize engineered tumor spheroids in static culture and exhibit limited duration of viability and poor correlations to human in vivo response
  • Development of a dynamic microfluidic model that accommodates biopsied tumor fragments with real-time quantitation of tumor killing and lymphocyte infiltration

12:10 pm Lunch & Networking

1:10 pm Using 3D Models to Investigate Mechanisms of Relieving Suppression of TME

  • William Hastings Exploratory ImmunoOncology Investigator , Novartis Institute of Biomedical Research


  • Performing compound profiling of targeted IO combination therapies in 3D models to aid in-vitro in-vivo translation
  • Analyzing immune suppressive features of co-culture
  • Highlighting the applications of co-culture to profiling targeted therapies using multiple readouts

1:40 pm Panel Discussion: Incorporating the Immune Component – Requirements for IO Models When Mimicking the Microenvironment in a Dish


  • What are the limitations to IO & where do you draw the line for their utility?
  • How do we avoid biasing model design and ensure that these systems are representative of patient responses?
  • To what degree of complexity should we align models to human-TME complexity?
  • Can we ever accurately model ME effects in a dish?
  • How can we overcome the current challenges of incorporating the immune and stromal components?

2:10 pm Afternoon Refreshments and Poster Session

3:10 pm Jellagen®: A Next Generation Jellyfish Collagen Matrix Offering New Opportunities for 3D Cell Culture


  • An introduction to jellyfish collagen and its potential for new avenues in cell culture applications
  • From 2D to 3D Jellagen® cell culture
  • Cell culture case studies demonstrating the potential advantages of jellyfish collagen

3:40 pm Roundtable Discussions:


Picking up on the days presentations, this session acts as an opportunity to drive your own learning, crowdsource ideas and discover multiple perspectives for driving the internal confidence in 3D. Over the hour, each breakout will discuss the below questions. Feedback from each group will collated and presented as part of the moderator panel.

4:30 pm Round Table – Moderator Feedback

4:45 pm Close of Conference Day One